Equivalence trial of tribendimidine versus albendazole against hookworm infections in Ivory Coast

Submission date	Recruitment status	[X] Prospectively registered
21/01/2006	No longer recruiting	<pre>Protocol</pre>
Registration date	Overall study status	Statistical analysis plan
24/01/2006	Completed	Results
Last Edited	Condition category	Individual participant data
25/08/2011	Infections and Infestations	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Eliezer N'Goran

Contact details

Laboratory of Zoology UFR Biosciences University of Cocody 22 BP 682 Abidjan Côte d'Ivoire 22 +225 05 07 65 81 eliezerngoran@yahoo.fr

Additional identifiers

Protocol serial number PPOOB-102883

Study information

Scientific Title

Acronym

TribenAlben

Study objectives

Tribendimidine is not inferior to albendazole in curing hookworm infections in young adult males

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics review of the clinical trial protocol was conducted by the Minister of Population and Health, Republic of Ivory Coast (Ministere de la Sante et de la Population, Republique de Cote d'Ivoire) and approved according to document number 314/MEMSP/DGPS/DEPS/S-DPM on 20/07/2005

Study design

Curative, randomized, double-blind, equivalence, clinical trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hookworm infection (Necator americanus and Ancylostoma duodenale)

Interventions

Intervention group: single oral dose of 400 mg tribendimidine Control group: single oral dose of 400 mg albendazole

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Tribendimidine Albendazole

Primary outcome(s)

- 1. Cure rate at 21 day post-administration
- 2. Egg reduction rate at 21 day post-administration
- 3. Observed acute adverse events within 1-3 hours and solicited adverse events within 24 hours

Key secondary outcome(s))

Rate of perceived illness episodes throughout the 6 months follow-up period with 1 week recall period

Completion date

30/09/2006

Eligibility

Key inclusion criteria

Hookworm egg positive adult males (16-45 years) recruited at community survey in the region of Agboville (south Ivory Coast) with written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Male

Key exclusion criteria

- 1. Any abnormal medical condition judged by the investigating medical team
- 2. Hypersensitivity to albendazole or any other anthelmintic drug
- 3. Taken any anthelmintic drug during the last month before enrolment
- 4. Hookworm egg negative after 4 Kato-Katz thick smears done on two consecutive stool specimens

Date of first enrolment

26/01/2006

Date of final enrolment

30/09/2006

Locations

Countries of recruitment

Côte d'Ivoire

Study participating centre Laboratory of Zoology

Abidjan Côte d'Ivoire

22

Sponsor information

Organisation

Swiss Tropical Institute (Switzerland)

ROR

https://ror.org/03adhka07

Funder(s)

Funder type

Government

Funder Name

Swiss Tropical Institute (core funding)

Funder Name

Swiss National Science Foundation (PPOB-102883)

Alternative Name(s)

Schweizerischer Nationalfonds, Swiss National Science Foundation, Fonds National Suisse de la Recherche Scientifique, Fondo Nazionale Svizzero per la Ricerca Scientifica, Fonds National Suisse, Fondo Nazionale Svizzero, Schweizerische Nationalfonds, The Swiss National Science Foundation (SNSF), SNF, SNSF, FNS

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Switzerland

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary